NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Rani Therapeutics Holdings, Inc. (RANI) Stock Analysis

Rani Therapeutics Holdings, Inc. (RANI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RANI

$0.87

+$0.01 (+1.53%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RANI with… →

RANI Key Statistics

As of Sep 4, 2026
Trading
Open
$0.86
Previous Close
$0.85
Day's Range
0.85–0.88
52-Week Range
0.45–3.87
Volume
380.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.71
Valuation
Market Cap
$121.59M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
24.93
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.13
Financials (FY)
Revenue (FY)
$1.63M+58.85%
Net Income (FY)
−$29.67M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
115.42M
1-Year Return
+88.04%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
797.17K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RANI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−35.93%
2025−1.46%
2024−58.73%
2023−43.73%
2022−63.91%
2021 (partial year)+48.64%

As of September 4, 2026.

RANI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.63M−$29.67M−1817.1%
2024$1.03M−$30.02M−2920.0%
2023$0.00−$33.97M—
2022$0.00−$30.59M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.63M—−$38.31M−$29.67M−1817.1%
2024$1.03M—−$49.60M−$30.02M−2920.0%
2023$0.00—−$66.10M−$33.97M—
2022$0.00—−$63.45M−$30.59M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RANI Valuation vs Biotechnology Median

Median of 656 stocks
MetricRANIBiotechnology medianvs median
P/S ratio24.9315.2663% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Rani Therapeutics Holdings, Inc. (RANI) carries a market capitalisation of $121.59M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 69.

Over the past 52 weeks the price has ranged from $0.45 to $3.87. The most recent close on file for RANI is $0.87, dated September 4, 2026. That is +$0.01 (+1.53%) against the previous close. The latest close sits 94.38% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.63M. That is +58.85% against the prior fiscal year, when revenue was $1.03M. The same year closed with a net loss of $29.67M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.13.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $1.63M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 24.93 times revenue. On price-to-sales that is 63.34% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.71. Annualized volatility over the trailing 5 years is 151.97%. Over the trailing twelve months the price has returned +88.04%. Measured over 5 years, that is −46.53% a year compounded.

Growth & Income

No dividend is on file for RANI.

2026 is still running; the price is −35.93% year to date. The strongest complete calendar year on file is 2025 at −1.46%; the weakest is 2022 at −63.91%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Rani Therapeutics Holdings, Inc. (RANI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rani Therapeutics Holdings, Inc. RANI $121.59M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Rani Therapeutics Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Visit website →